Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Bladder Urothelial Carcinoma”

32 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 32 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03093922
What this trial is testing

Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Who this might be right for
Urothelial CarcinomaLocally AdvancedUnresectable
Memorial Sloan Kettering Cancer Center 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT04940299
What this trial is testing

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Bladder Carcinoma+39 more
M.D. Anderson Cancer Center 35
Testing effectiveness (Phase 2)Study completedNCT02178241
What this trial is testing

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

Who this might be right for
Metastatic Ureter CarcinomaMetastatic Urethral CarcinomaStage III Bladder Urothelial Carcinoma AJCC v6 and v7+7 more
National Cancer Institute (NCI) 26
Not applicableStudy completedNCT05902494
What this trial is testing

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 389
Testing effectiveness (Phase 2)Looking for participantsNCT05267626
What this trial is testing

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Who this might be right for
Advanced Solid TumorMetastatic CancerCutaneous Melanoma+1 more
Aulos Bioscience, Inc. 159
Testing effectiveness (Phase 2)Active Not RecruitingNCT03601455
What this trial is testing

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Who this might be right for
Bladder Urothelial CarcinomaStage IV Bladder Cancer AJCC v8Stage IVA Bladder Cancer AJCC v8+1 more
Jonsson Comprehensive Cancer Center 13
Testing effectiveness (Phase 2)WithdrawnNCT03935347
What this trial is testing

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Who this might be right for
Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial Carcinoma+3 more
Roswell Park Cancer Institute
Testing effectiveness (Phase 2)WithdrawnNCT06424717
What this trial is testing

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Who this might be right for
Urothelial Carcinoma
EMD Serono Research & Development Institute, Inc.
Testing effectiveness (Phase 2)Study completedNCT00478361
What this trial is testing

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Who this might be right for
Distal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterProximal Urethral Cancer+8 more
M.D. Anderson Cancer Center 40
Not applicableLooking for participantsNCT06138561
What this trial is testing

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

Who this might be right for
Bladder CancerMetastatic Bladder CancerUnresectable Bladder Carcinoma+1 more
Dana-Farber Cancer Institute 180
Testing effectiveness (Phase 2)Study completedNCT03513952
What this trial is testing

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Who this might be right for
Advanced Bladder Urothelial CarcinomaAdvanced Ureter Urothelial CarcinomaMetastatic Bladder Urothelial Carcinoma+21 more
National Cancer Institute (NCI) 47
Testing effectiveness (Phase 2)Active Not RecruitingNCT03237780
What this trial is testing

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Who this might be right for
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+21 more
National Cancer Institute (NCI) 72
Large-scale testing (Phase 3)Study completedNCT00942331
What this trial is testing

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Who this might be right for
Advanced Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Prostate Carcinoma+10 more
National Cancer Institute (NCI) 506
Testing effectiveness (Phase 2)Looking for participantsNCT07667335
What this trial is testing

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

Who this might be right for
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+10 more
Fred Hutchinson Cancer Center 27
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07625527
What this trial is testing

Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNon Muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT04953104
What this trial is testing

ARID1A and/or KDM6A Mutation and CXCL13 Expression

Who this might be right for
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+29 more
M.D. Anderson Cancer Center 6
Testing effectiveness (Phase 2)Ended earlyNCT01234519
What this trial is testing

A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy

Who this might be right for
Urothelial Carcinoma
AEterna Zentaris 12
Early research (Phase 1)Ended earlyNCT06714617
What this trial is testing

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Who this might be right for
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more
SystImmune Inc. 3
Testing effectiveness (Phase 2)UnknownNCT01118039
What this trial is testing

Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
Hospital del Mar 41
Early research (Phase 1)Looking for participantsNCT04878029
What this trial is testing

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Who this might be right for
Infiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+1 more
Emory University 32
Next Page